Minerva Neurosciences appoints Dr. Inderjit Kaul to board; Kaul led Cobenfy schizophrenia program at BMS

Minerva Neurosciences, Inc.

Dr. Kaul appointed to Minerva's board (Class II) effective Nov 14, 2025; board size increased to 6.
Received initial option grant of 9,500 shares vesting quarterly over 3 years; $40,000 annual cash retainer.
Consulting agreement: $450/hr for 25-30 hrs/month, six-month term; equity top-ups tied to roluperidone milestones.
Kaul previously SVP Late-Stage Clinical Development at BMS, led Cobenfy development for schizophrenia; currently CMO of Draig Therapeutics.
Appointment follows recent $200M private placement to fund confirmatory Phase 3 trial of roluperidone.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.